Trevena Inc (TRVN)

[GoodGuyBill]

REVERSE STOCK SPLIT COMING!!!!!!

https://docoh.com/filing/1429560/0001104659-21-095146/TRVN-DEFA14A

CHESTERBROOK, PA., Jul. 23, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Glass Lewis and ISS, two independent, leading proxy advisory firms, have both recommended that Trevena shareholders vote “FOR” Proposals 1 & 2 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on July 6, 2021 in connection with its Special Meeting of Stockholders, which seek to amend Trevena’s Amended and Restated Certificate of Incorporation to approve a Reverse Stock Split and concurrent Authorized Share Reduction. The Special Meeting will be held on August 9, 2021 at 8:30 a.m. ET and will be held virtually at www.virtualshareholdermeeting.com/TRVN2021SM.

"We greatly appreciate the third-party, independent recommendations from both Glass Lewis and ISS," said Carrie Bourdow, President and CEO of Trevena. "Trevena has had a transformational year and these proposals are key to positioning the company for continued long term growth, as detailed in our Proxy Statement."

Glass Lewis and ISS are widely recognized as two of the leading independent proxy voting and corporate governance advisory firms. Their recommendations are relied upon by institutional investment firms, mutual funds, and other fiduciaries globally. Glass Lewis and ISS are independent proxy advisory firms and do not have any business relationship with Trevena. Trevena did not engage or compensate either firm for its analysis or recommendations.

Trevena shareholders are urged to vote as Glass Lewis and ISS recommend by voting “FOR” the two proposals detailed below:

· Proposal 1: Approval of a reverse stock split of our issued and outstanding shares of common stock at a ratio of one (1) share of common stock for every four (4) shares of common stock (the “Reverse Stock Split”), to be effected through an amendment to our amended and restated certificate of incorporation (as amended, the “Restated Certificate”); and

· Proposal 2: Approval to decrease the number of authorized shares of common stock from 200,000,000 to 100,000,000 (the “Authorized Share Reduction”), contingent upon and concurrent with the Reverse Stock Split, to be effected through an amendment to the Restated Certificate.

[megatron31]

-8% apparently
:(

[megatron31]

What will tomorrow’s (5/6/21) 1Q earnings bring?
~TRVN~

[$Pistol Pete$]

I will buy back when it hit $1

[ClayTrader]

* * $TRVN Video Chart 04-16-2021 * *

Link to Video - click here to watch the technical chart video

[kijia]

It's time to roll!!!


Go TRVN$$$

[longboarder7892]

Looks like its time to get back into TRVN

[GoodGuyBill]

An upcomming proxy proposal:

https://docoh.com/filing/1429560/0001104659-21-043354/TRVN-PRE14A

Proposal 4: Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000.

[ChillingPenguin]

I was speaking about that week, but was hoping for news on my failed calls. Holding my shares for the year, but valuate my position on a quarterly basis. Still waiting on trial results 1h of 2021.

[Johnny_C]

Why do you say this week. Been holding patiently adding here and there. Drug seems promising though.

[longboarder7892]

Looking very good glad I added down there. Lets see what $3.00 feels like today. On the highs of 2.88 right now. Ill check back in after 9 holes of golf. this last buy was a no brainer for me.

[WindowCleaner4Life]

Man this has been a good performer in the past 2 weeks trading. Im looking for more upside from the 2.60 handle
Glta

[ChillingPenguin]

You think $3 next week maybe? News on covid play would be fantastic

[longboarder7892]

Very nice TRVN keep it going

[ChillingPenguin]

Ok, thanks. I have a few options expiring 2/19 for 2.50, I appreciate your insight. Going to be a great week!!

[WindowCleaner4Life]

No news. Assive volume. This stock looks like its ready to breakout

[ChillingPenguin]

What news you have? Or are you just speculating?

[WindowCleaner4Life]

Buckle up. We going for a ride

[longboarder7892]

Happy I added some more TRVN last week. Lets see if it can put on .20 or .30 this week and hold them.

[KevGee59]

It kinda looks like an inverse h&s pattern on the Daily from October 28th.

It's still in the wedge also...headed for the apex. About a month out.

KG ;)

[ListenToMe]

Idk why Trvn Can't Break Out!

[KevGee59]

Nice close...

Slow grind up from here IMO

KG ;)

[longboarder7892]

Happy to be back in TRVN Bot the tax loss sellers shares.$$$$$

[RNsidersbuying]

COVID-19 trial for TRV027 on track to report topline data this quarter. TRV027 is being evaluated in a 60-person trial as a potential treatment for acute lung damage / abnormal blood clotting associated with COVID-19. Imperial College London is sponsoring and funding the study, with additional support through the British Heart Foundation Centre for Research Excellence Award.

[senderos]

Trevena, Inc. Provides Update on Commercial Launch Activities for OLINVYK™ and Announces Anticipated Pipeline Catalysts
BY GlobeNewswire
— 7:00 AM ET 01/06/2021

--

Build-out of customer-facing team on track for this quarter

OLINVYK comprehensive product dossier / health economic model now available to facilitate formulary reviews

--

CHESTERBROOK, Pa., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. ( TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today provided an update on the U.S. commercial launch for OLINVYK (oliceridine) injection and announced anticipated milestones for 2021.

“We enter 2021 focused on building upon the foundation we laid in 2020 to deliver a successful launch for OLINVYK. I’m pleased by the early interest we’ve received from hospital physicians and institutions across the country,” said Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. ( TRVN) “Additionally, we continue to make exciting progress across our pipeline, with several upcoming catalysts this year.”

OLINVYK Commercial Launch

OLINVYK commercially available. The Company has contracted with the three major wholesalers covering the majority of the acute care business. All three vial presentations of OLINVYK (1 mg/1 mL and 2 mg/2 mL single-dose vials; 30 mg/30 mL single-patient-use vials for patient-controlled analgesia) are now available for ordering.

Ramp-up of customer engagement activities underway. Since the approval of OLINVYK, the Company has received inbound interest from a diverse set of institutions and engaged with a number of key opinion leaders who participated in the Phase 3 OLINVYK “real-world” multi-site safety study. Physicians continue to reinforce the value proposition of OLINVYK as a compelling new analgesic option for acute pain patients in the hospital and other controlled clinical settings.

The comprehensive product dossier and detailed health economic model for OLINVYK are now complete and accessible to healthcare decision makers to facilitate formulary inclusion. The health economic model, which highlights OLINVYK versus IV morphine cost information, is expected to be published in 1H 2021.

In addition, the “Now Available” marketing campaign for OLINVYK has launched, which includes early digital engagement, launch emails to targeted healthcare professionals, and an updated website which provides product ordering and reimbursement information.

Build-out of customer-facing team on track for deployment this quarter. The Company has completed hiring of its medical science liaisons (MSLs) and sales manager team, and it remains on track to complete hiring, training and deployment of its field commercial team this quarter. The Company today announced that it will be targeting 100 formulary acceptances in 2021. In response to the ongoing COVID-19 pandemic, the Company is employing analytics on a local and regional basis to monitor the impact on hospitals and ambulatory surgical centers, and to inform the safe and effective deployment of its customer-facing teams.

All required CMS reimbursement submissions and registrations complete. The Company today announced that all submissions for permanent J- and C-Codes have been submitted to the Centers for Medicare and Medicaid Services (CMS) for OLINVYK. In the interim, as is customary for all new products, customers will use the miscellaneous J- and C-codes for reimbursement. This ensures that OLINVYK can be reimbursed in both the inpatient and outpatient setting until permanent codes are established. Market access resources are now available to customers which support reimbursement of OLINVYK at 95% of Average Wholesale Price (AWP) in advance of pass-through status being decided.

Pipeline Updates

COVID-19 trial for TRV027 on track to report topline data this quarter. TRV027 is being evaluated in a 60-person trial as a potential treatment for acute lung damage / abnormal blood clotting associated with COVID-19. Imperial College London is sponsoring and funding the study, with additional support through the British Heart Foundation Centre for Research Excellence Award.

IND filing for TRV045 on track for 1H 2021. In December 2020, the Company presented nonclinical data supporting the potential utility of TRV045 to treat a variety of CNS disorders, including epilepsy, chemotherapy-induced peripheral neuropathy, and diabetic peripheral neuropathy. The Company is currently collaborating with the National Institutes of Health (NIH) to evaluate TRV045 in their screening programs for epilepsy and non-addictive treatment of pain.

[GoodGuyBill]

oops...should have knocked on wood, lol.

[GoodGuyBill]

We've been up almost every day for the last week or so. Hope it continues.

[Jimcal22]

Yes for sure’

[CalMustang]

Agree with you except for #3

3. Perceived relative lack of need for pipeline drug TRV027 now that Covid vaccines are becoming available.

TRVN was trading higher pre-covid. If anything, this was a bonus that was not realized until covid, and should be adding to the PPS, and at worst, be neutral -- not taking away.

[CalMustang]

Yep. I'm sure we both wish JT had taken whatever offers he had for AMRN when it was trading in the teens and 20s.

[$Pistol Pete$]

Yes and it will be good for long term hold

[fishon101]

Pete, this one is set to fly for the longs.

[$Pistol Pete$]

$TRVN bought too quick for a quick flip

[$Pistol Pete$]

Probably bought too quick for the gain

[GoodGuyBill]

Sometimes I wonder if we will stay above 1.50...

[fastlane2000]

Herbie I would like to see that $5 , But it seems to be hard to hold $3 .

[HerbieRay]

So the market obviously does not see an opportunity for price appreciation in TRVN in the short term. Hence they are taking their money out in putting it in cyclical stocks.
I still have a good long term (1-3 yr) outlook for this stock and am still dollar cost averaging buying some every 2 weeks. But this isnt the only horse I have in the race.
I still believe the one year price target of 5 to $6 based on their potential sales ramp up.

[ListenToMe]

I'm expecting a PARABOLIC move UP to take TRVN above $5. Then more institutional buyers will start buying.

TRVN

[HerbieRay]

I'm guessing that the short term pullback and "holding pattern" in TRVN is due to a few factors:
1. Market obsession with reentry into the popular market stocks and ETFs and need to generate capital for investing in those.
2. Shorting ease due to little/no TRVN news in near term.
3. Perceived relative lack of need for pipeline drug TRV027 now that Covid vaccines are becoming available.

At any rate, I'm looking at these as short term phenomena and price consolidation and am averaging in to take advantage while they are ramping up for OLINVYK promotion and/or BO.

Comments are always welcome for sanity check.

LONG TRVN
HerbieRay

[ListenToMe]

Well said. TRVN definitely has Big potential and we need to watch for the behind tge scenes activity to give us an indication of what's to come.


TRVN

[couldbebetter]

Option premiums are quite high on TRVN...If there were anything to the
rumor I would think it would be trading closer to $4.00. Small Bios
with potential blockbuster products should always be sold to BP if they
get a reasonable offer. $8.25 would be reasonable in my book. I would
think if TRVN were GIA they would be hiring and training a significant
sales force right now. So far I don't see that right now. At under $3.00
this is way undervalued.

[HerbieRay]

I haven't heard anything.
B/O rumors are common in these Bios.
AMRN went through these for 2 years or more.
I'll keep my ears to the rail though.

HRS

[ListenToMe]

Clinical report out: TRVN
Oliceridine reduces post-op respiratory depression 4-fold(!) over morphine in patients treated for moderate/severe pain:

Pain Res Manag ;2020:7492865. doi: 10.1155/2020/7492865. eCollection 2020.

Low Incidence of Postoperative Respiratory Depression with Oliceridine Compared to Morphine: A Retrospective Chart Analysis

Sergio Bergese 1, Richard Berkowitz 2, Paul Rider 3, Martin Ladouceur 4, Suzanne Griffith 5, Alvaro Segura Vasi 6, Kristina Cochrane 7, Linda Wase 7, Mark A Demitrack 7, Ashraf S Habib 8

PMID: 33163127 PMCID: PMC7604609 DOI: 10.1155/2020/7492865
Abstract
Background: Oliceridine, an investigational IV opioid, is a first-in-class G-protein selective agonist at the µ-opioid receptor. The G-protein selectivity results in potent analgesia with less recruitment of ß-arrestin, a signaling pathway associated with opioid-related adverse events (ORAEs). In randomized controlled studies in both hard and soft tissue models yielding surgical pain, oliceridine provided effective analgesia with a potential for an improved safety and tolerability profile at equianalgesic doses to morphine. The phase 3, open-label, single-arm, multicenter ATHENA trial demonstrated the safety, tolerability, and effectiveness of oliceridine in moderate to severe acute pain in a broad range of patients undergoing surgery or with painful medical conditions warranting use of an IV opioid. This retrospective, observational chart review study compared respiratory depression events associated with oliceridine administration as found in the ATHENA trial to a control cohort treated with conventional opioids.

Methods: Patients at 18 years of age or older, who underwent colorectal, orthopedic, cardiothoracic, bariatric, or general surgeries between June 2015 and May 2017 in 11 sites participating in the ATHENA trial who received postoperative analgesia either with IV oliceridine or with IV conventional opioids (e.g., morphine alone or in combination with other opioids) (CO cohort); and had a hospital stay >48 hours, were included in this retrospective analysis. Data from the ATHENA trial was used for the oliceridine cohort; and additional baseline characteristics were collected from medical charts. Data from medical charts were collected for all CO cohort patients. The two cohorts were balanced using an inverse probability weighting method. The primary outcome was the incidence of operationally defined opioid-induced respiratory depression (OIRD) in the two cohorts. Secondary outcomes included between-group comparison of the incidence of OIRD events among a subset of high-risk patients.

Results: OIRD was significantly less in the oliceridine cohort compared to the CO cohort (8.0% vs. 30.7%; odds ratio: 0.139) (95% confidence interval [CI] 0.09-0.22; P < 0.0001). Likewise, the incidence of OIRD was lower among high-risk patients in the oliceridine cohort (9.1% vs. 34.7%; odds ratio: 0.136) (95% CI [0.09-0.22]; P < 0.0001) compared to the CO cohort.

Conclusion: In this retrospective chart review study, patients receiving IV oliceridine for moderate to severe acute pain demonstrated a lower incidence of treatment emergent OIRD compared to patients who were treated with IV morphine either alone or with concomitant administration of other opioids.

[ListenToMe]

$8.25 is Wayyy too low!!!

Maybe $28.25 ...now thats more realistic!


TRVN

[Retiredceo]

There’s a buyout rumor for $8.25 on YMB. Supposedly from Reddit. Any substance to this?

[ListenToMe]

Just sayin... TRVN

[ListenToMe]

This is the month for TRVN to Shine!!

[ListenToMe]

Lots of news anticipated for November and it is All Good!!

TRVN

[ListenToMe]

HUGE HUGE potential here for TRVN!!

[longboarder7892]

Have full position again with 100k shares picked them up yesterday and today close to the placement price. The back and fill was very bullish for the the mid term.Good luck to the longs.............